PTC Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $13.23M, a 1067.02% increase year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $6.40M, a 59.35% decline year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $59.39M, a 155.48% increase year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $16.83M, a 2837.17% increase year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $93.10M, a 225.93% increase from fiscal 2024.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $28.57M, a 18.82% increase from fiscal 2023.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $24.04M, a 64.30% increase from fiscal 2022.
- PTC Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $14.63M, a 15.47% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $13.23M 10-Q · filed 2026-07-30 | $95.85M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $6.40M 10-Q · filed 2026-05-07 | $83.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $59.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $93.10M 10-K · filed 2026-02-19 |
| 2025-09-30 | $16.83M 10-Q · filed 2025-11-04 | $56.96M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.13M 10-Q · filed 2026-07-30 | $40.70M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $15.75M 10-Q · filed 2026-05-07 | $42.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $23.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $28.57M 10-K · filed 2026-02-19 |
| 2024-09-30 | $573.00K 10-Q · filed 2025-11-04 | $5.51M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $2.64M 10-Q · filed 2025-08-07 | $8.38M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $2.03M 10-Q · filed 2025-05-06 | $20.02M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $24.04M 10-K · filed 2026-02-19 |
| 2023-09-30 | $3.45M 10-Q · filed 2024-11-07 | $24.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $14.27M 10-Q · filed 2024-08-08 | $31.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.66M 10-Q · filed 2024-04-25 | $17.84M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.63M 10-K · filed 2025-02-27 |
| 2022-09-30 | $10.01M 10-Q · filed 2023-10-26 | $14.39M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $754.00K 10-Q · filed 2023-08-03 | $7.36M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.44M 10-Q · filed 2023-04-27 | $8.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $17.31M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.98M 10-Q · filed 2022-10-27 | $53.31M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $1.39M 10-Q · filed 2022-08-04 | $58.28M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $11.76M 10-Q · filed 2022-05-03 | $71.95M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $37.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $70.18M 10-K · filed 2023-02-21 |
| 2020-09-30 | $7.94M 10-Q · filed 2021-10-28 | $39.07M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $15.06M 10-Q · filed 2021-07-29 | $38.21M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $9.99M 10-Q · filed 2021-05-04 | $26.00M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $18.28M 10-K · filed 2022-02-22 |
| 2019-09-30 | $7.09M 10-Q · filed 2020-10-29 | $13.45M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.85M 10-Q · filed 2020-08-05 | $11.40M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.28M 10-Q · filed 2020-04-30 | $11.01M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $10.87M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.04M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $2.46M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $1.14M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $2.18M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $968.00K 10-K · filed 2019-03-01 | |
| 2015-12-31 | $8.71M 10-K · filed 2018-03-06 | |
| 2014-12-31 | $1.20M 10-K · filed 2017-03-16 | |
| 2011-12-31 | $5.89K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |